DrugPatentWatch Database Preview
Drugs in Development Information for Lumacaftor
» See Plans and Pricing
What is the development status for investigational drug Lumacaftor?
Lumacaftor is an investigational drug.
There have been 36 clinical trials for Lumacaftor.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2018.
The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Lung Diseases. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated, Massachusetts General Hospital, and Children's Hospital Medical Center, Cincinnati.
There are one hundred and six US patents protecting this investigational drug and one international patent.
Summary for Lumacaftor
| US Patents | 106 |
| International Patents | 1,047 |
| US Patent Applications | 211 |
| WIPO Patent Applications | 366 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2018-10-01) |
| Vendors | 86 |
Recent Clinical Trials for Lumacaftor
| Title | Sponsor | Phase |
|---|---|---|
| Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials | Children's Hospital Medical Center, Cincinnati | N/A |
| Mutation-specific Therapy for the Long QT Syndrome | Istituto Auxologico Italiano | Phase 2 |
| Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation | Vertex Pharmaceuticals Incorporated | Phase 3 |
Clinical Trial Summary for Lumacaftor
Top disease conditions for Lumacaftor
Top clinical trial sponsors for Lumacaftor
US Patents for Lumacaftor
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Lumacaftor | Start Trial | Compounds, compositions, and methods for increasing CFTR activity | Proteostasis Therapeutics, Inc. (Boston, MA) | Start Trial |
| Lumacaftor | Start Trial | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| Lumacaftor | Start Trial | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof | Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| Lumacaftor | Start Trial | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-- fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxa- mide | Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Lumacaftor
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Lumacaftor | Australia | AU2015229117 | 2034-03-13 | Start Trial |
| Lumacaftor | Canada | CA2942387 | 2034-03-13 | Start Trial |
| Lumacaftor | European Patent Office | EP3116870 | 2034-03-13 | Start Trial |
| Lumacaftor | World Intellectual Property Organization (WIPO) | WO2015138934 | 2034-03-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
